The global Cancer Minimal Residual Disease Testing market size is predicted to grow from US$ 1147 million in 2025 to US$ 1746 million in 2031; it is expected to grow at a CAGR of 7.3% from 2025 to 2031.
Minimal residual disease (MRD) is听a term used to describe the small number of cancer cells in the body after cancer treatment. An MRD positive test result means that disease was still detected after treatment. An MRD negative result means that no disease was detected after treatment.
The market for cancer MRD testing is likely to grow as precision medicine and personalized treatment approaches become more prominent in cancer care. MRD testing can play a significant role in tailoring treatment plans to individual patients.
The 鈥淐ancer Minimal Residual Disease Testing Industry Forecast鈥� looks at past sales and reviews total world Cancer Minimal Residual Disease Testing sales in 2024, providing a comprehensive analysis by region and market sector of projected Cancer Minimal Residual Disease Testing sales for 2025 through 2031. With Cancer Minimal Residual Disease Testing sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Cancer Minimal Residual Disease Testing industry.
This Insight Report provides a comprehensive analysis of the global Cancer Minimal Residual Disease Testing landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Cancer Minimal Residual Disease Testing portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms鈥� unique position in an accelerating global Cancer Minimal Residual Disease Testing market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Cancer Minimal Residual Disease Testing and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Cancer Minimal Residual Disease Testing.
This report presents a comprehensive overview, market shares, and growth opportunities of Cancer Minimal Residual Disease Testing market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
Flow Cytometry
Polymerase Chain Reaction (PCR)
Next-Generation Sequencing (NGS)
Other
Segmentation by Application:
Hematological Malignancies
Leukemia
Lymphoma
Solid Tumors
Other
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Adaptive Biotechnologies Corporation
ArcherDX, Inc. (Invitae Corporation)
Asuragen
Arup Laboratories
Bio-Rad Laboratories
Cergentis B.V.
F. Hoffmann- La Roche Ltd
Guardant Health
ICON plc
Invivoscribe
Laboratory Corporation of America Holdings
Mission Bio
Natera, Inc.
NeoGenomics Laboratories
Opko Health
Quest Diagnostics Incorporated
Sysmex Corporation
Genetron Health
Key Questions Addressed in this Report
What is the 10-year outlook for the global Cancer Minimal Residual Disease Testing market?
What factors are driving Cancer Minimal Residual Disease Testing market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Cancer Minimal Residual Disease Testing market opportunities vary by end market size?
How does Cancer Minimal Residual Disease Testing break out by Type, by Application?
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Scope of the Report
1.1 麻豆原创 Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 麻豆原创 Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 麻豆原创 Estimation Caveats
2 Executive Summary
2.1 World 麻豆原创 Overview
2.1.1 Global Cancer Minimal Residual Disease Testing Annual Sales 2020-2031
2.1.2 World Current & Future Analysis for Cancer Minimal Residual Disease Testing by Geographic Region, 2020, 2024 & 2031
2.1.3 World Current & Future Analysis for Cancer Minimal Residual Disease Testing by Country/Region, 2020, 2024 & 2031
2.2 Cancer Minimal Residual Disease Testing Segment by Type
2.2.1 Flow Cytometry
2.2.2 Polymerase Chain Reaction (PCR)
2.2.3 Next-Generation Sequencing (NGS)
2.2.4 Other
2.3 Cancer Minimal Residual Disease Testing Sales by Type
2.3.1 Global Cancer Minimal Residual Disease Testing Sales 麻豆原创 Share by Type (2020-2025)
2.3.2 Global Cancer Minimal Residual Disease Testing Revenue and 麻豆原创 Share by Type (2020-2025)
2.3.3 Global Cancer Minimal Residual Disease Testing Sale Price by Type (2020-2025)
2.4 Cancer Minimal Residual Disease Testing Segment by Application
2.4.1 Hematological Malignancies
2.4.2 Leukemia
2.4.3 Lymphoma
2.4.4 Solid Tumors
2.4.5 Other
2.5 Cancer Minimal Residual Disease Testing Sales by Application
2.5.1 Global Cancer Minimal Residual Disease Testing Sale 麻豆原创 Share by Application (2020-2025)
2.5.2 Global Cancer Minimal Residual Disease Testing Revenue and 麻豆原创 Share by Application (2020-2025)
2.5.3 Global Cancer Minimal Residual Disease Testing Sale Price by Application (2020-2025)
3 Global by Company
3.1 Global Cancer Minimal Residual Disease Testing Breakdown Data by Company
3.1.1 Global Cancer Minimal Residual Disease Testing Annual Sales by Company (2020-2025)
3.1.2 Global Cancer Minimal Residual Disease Testing Sales 麻豆原创 Share by Company (2020-2025)
3.2 Global Cancer Minimal Residual Disease Testing Annual Revenue by Company (2020-2025)
3.2.1 Global Cancer Minimal Residual Disease Testing Revenue by Company (2020-2025)
3.2.2 Global Cancer Minimal Residual Disease Testing Revenue 麻豆原创 Share by Company (2020-2025)
3.3 Global Cancer Minimal Residual Disease Testing Sale Price by Company
3.4 Key Manufacturers Cancer Minimal Residual Disease Testing Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Cancer Minimal Residual Disease Testing Product Location Distribution
3.4.2 Players Cancer Minimal Residual Disease Testing Products Offered
3.5 麻豆原创 Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.6 New Products and Potential Entrants
3.7 麻豆原创 M&A Activity & Strategy
4 World Historic Review for Cancer Minimal Residual Disease Testing by Geographic Region
4.1 World Historic Cancer Minimal Residual Disease Testing 麻豆原创 Size by Geographic Region (2020-2025)
4.1.1 Global Cancer Minimal Residual Disease Testing Annual Sales by Geographic Region (2020-2025)
4.1.2 Global Cancer Minimal Residual Disease Testing Annual Revenue by Geographic Region (2020-2025)
4.2 World Historic Cancer Minimal Residual Disease Testing 麻豆原创 Size by Country/Region (2020-2025)
4.2.1 Global Cancer Minimal Residual Disease Testing Annual Sales by Country/Region (2020-2025)
4.2.2 Global Cancer Minimal Residual Disease Testing Annual Revenue by Country/Region (2020-2025)
4.3 Americas Cancer Minimal Residual Disease Testing Sales Growth
4.4 APAC Cancer Minimal Residual Disease Testing Sales Growth
4.5 Europe Cancer Minimal Residual Disease Testing Sales Growth
4.6 Middle East & Africa Cancer Minimal Residual Disease Testing Sales Growth
5 Americas
5.1 Americas Cancer Minimal Residual Disease Testing Sales by Country
5.1.1 Americas Cancer Minimal Residual Disease Testing Sales by Country (2020-2025)
5.1.2 Americas Cancer Minimal Residual Disease Testing Revenue by Country (2020-2025)
5.2 Americas Cancer Minimal Residual Disease Testing Sales by Type (2020-2025)
5.3 Americas Cancer Minimal Residual Disease Testing Sales by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Cancer Minimal Residual Disease Testing Sales by Region
6.1.1 APAC Cancer Minimal Residual Disease Testing Sales by Region (2020-2025)
6.1.2 APAC Cancer Minimal Residual Disease Testing Revenue by Region (2020-2025)
6.2 APAC Cancer Minimal Residual Disease Testing Sales by Type (2020-2025)
6.3 APAC Cancer Minimal Residual Disease Testing Sales by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Cancer Minimal Residual Disease Testing by Country
7.1.1 Europe Cancer Minimal Residual Disease Testing Sales by Country (2020-2025)
7.1.2 Europe Cancer Minimal Residual Disease Testing Revenue by Country (2020-2025)
7.2 Europe Cancer Minimal Residual Disease Testing Sales by Type (2020-2025)
7.3 Europe Cancer Minimal Residual Disease Testing Sales by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Cancer Minimal Residual Disease Testing by Country
8.1.1 Middle East & Africa Cancer Minimal Residual Disease Testing Sales by Country (2020-2025)
8.1.2 Middle East & Africa Cancer Minimal Residual Disease Testing Revenue by Country (2020-2025)
8.2 Middle East & Africa Cancer Minimal Residual Disease Testing Sales by Type (2020-2025)
8.3 Middle East & Africa Cancer Minimal Residual Disease Testing Sales by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 麻豆原创 Drivers, Challenges and Trends
9.1 麻豆原创 Drivers & Growth Opportunities
9.2 麻豆原创 Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Cancer Minimal Residual Disease Testing
10.3 Manufacturing Process Analysis of Cancer Minimal Residual Disease Testing
10.4 Industry Chain Structure of Cancer Minimal Residual Disease Testing
11 麻豆原创ing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Cancer Minimal Residual Disease Testing Distributors
11.3 Cancer Minimal Residual Disease Testing Customer
12 World Forecast Review for Cancer Minimal Residual Disease Testing by Geographic Region
12.1 Global Cancer Minimal Residual Disease Testing 麻豆原创 Size Forecast by Region
12.1.1 Global Cancer Minimal Residual Disease Testing Forecast by Region (2026-2031)
12.1.2 Global Cancer Minimal Residual Disease Testing Annual Revenue Forecast by Region (2026-2031)
12.2 Americas Forecast by Country (2026-2031)
12.3 APAC Forecast by Region (2026-2031)
12.4 Europe Forecast by Country (2026-2031)
12.5 Middle East & Africa Forecast by Country (2026-2031)
12.6 Global Cancer Minimal Residual Disease Testing Forecast by Type (2026-2031)
12.7 Global Cancer Minimal Residual Disease Testing Forecast by Application (2026-2031)
13 Key Players Analysis
13.1 Adaptive Biotechnologies Corporation
13.1.1 Adaptive Biotechnologies Corporation Company Information
13.1.2 Adaptive Biotechnologies Corporation Cancer Minimal Residual Disease Testing Product Portfolios and Specifications
13.1.3 Adaptive Biotechnologies Corporation Cancer Minimal Residual Disease Testing Sales, Revenue, Price and Gross Margin (2020-2025)
13.1.4 Adaptive Biotechnologies Corporation Main Business Overview
13.1.5 Adaptive Biotechnologies Corporation Latest Developments
13.2 ArcherDX, Inc. (Invitae Corporation)
13.2.1 ArcherDX, Inc. (Invitae Corporation) Company Information
13.2.2 ArcherDX, Inc. (Invitae Corporation) Cancer Minimal Residual Disease Testing Product Portfolios and Specifications
13.2.3 ArcherDX, Inc. (Invitae Corporation) Cancer Minimal Residual Disease Testing Sales, Revenue, Price and Gross Margin (2020-2025)
13.2.4 ArcherDX, Inc. (Invitae Corporation) Main Business Overview
13.2.5 ArcherDX, Inc. (Invitae Corporation) Latest Developments
13.3 Asuragen
13.3.1 Asuragen Company Information
13.3.2 Asuragen Cancer Minimal Residual Disease Testing Product Portfolios and Specifications
13.3.3 Asuragen Cancer Minimal Residual Disease Testing Sales, Revenue, Price and Gross Margin (2020-2025)
13.3.4 Asuragen Main Business Overview
13.3.5 Asuragen Latest Developments
13.4 Arup Laboratories
13.4.1 Arup Laboratories Company Information
13.4.2 Arup Laboratories Cancer Minimal Residual Disease Testing Product Portfolios and Specifications
13.4.3 Arup Laboratories Cancer Minimal Residual Disease Testing Sales, Revenue, Price and Gross Margin (2020-2025)
13.4.4 Arup Laboratories Main Business Overview
13.4.5 Arup Laboratories Latest Developments
13.5 Bio-Rad Laboratories
13.5.1 Bio-Rad Laboratories Company Information
13.5.2 Bio-Rad Laboratories Cancer Minimal Residual Disease Testing Product Portfolios and Specifications
13.5.3 Bio-Rad Laboratories Cancer Minimal Residual Disease Testing Sales, Revenue, Price and Gross Margin (2020-2025)
13.5.4 Bio-Rad Laboratories Main Business Overview
13.5.5 Bio-Rad Laboratories Latest Developments
13.6 Cergentis B.V.
13.6.1 Cergentis B.V. Company Information
13.6.2 Cergentis B.V. Cancer Minimal Residual Disease Testing Product Portfolios and Specifications
13.6.3 Cergentis B.V. Cancer Minimal Residual Disease Testing Sales, Revenue, Price and Gross Margin (2020-2025)
13.6.4 Cergentis B.V. Main Business Overview
13.6.5 Cergentis B.V. Latest Developments
13.7 F. Hoffmann- La Roche Ltd
13.7.1 F. Hoffmann- La Roche Ltd Company Information
13.7.2 F. Hoffmann- La Roche Ltd Cancer Minimal Residual Disease Testing Product Portfolios and Specifications
13.7.3 F. Hoffmann- La Roche Ltd Cancer Minimal Residual Disease Testing Sales, Revenue, Price and Gross Margin (2020-2025)
13.7.4 F. Hoffmann- La Roche Ltd Main Business Overview
13.7.5 F. Hoffmann- La Roche Ltd Latest Developments
13.8 Guardant Health
13.8.1 Guardant Health Company Information
13.8.2 Guardant Health Cancer Minimal Residual Disease Testing Product Portfolios and Specifications
13.8.3 Guardant Health Cancer Minimal Residual Disease Testing Sales, Revenue, Price and Gross Margin (2020-2025)
13.8.4 Guardant Health Main Business Overview
13.8.5 Guardant Health Latest Developments
13.9 ICON plc
13.9.1 ICON plc Company Information
13.9.2 ICON plc Cancer Minimal Residual Disease Testing Product Portfolios and Specifications
13.9.3 ICON plc Cancer Minimal Residual Disease Testing Sales, Revenue, Price and Gross Margin (2020-2025)
13.9.4 ICON plc Main Business Overview
13.9.5 ICON plc Latest Developments
13.10 Invivoscribe
13.10.1 Invivoscribe Company Information
13.10.2 Invivoscribe Cancer Minimal Residual Disease Testing Product Portfolios and Specifications
13.10.3 Invivoscribe Cancer Minimal Residual Disease Testing Sales, Revenue, Price and Gross Margin (2020-2025)
13.10.4 Invivoscribe Main Business Overview
13.10.5 Invivoscribe Latest Developments
13.11 Laboratory Corporation of America Holdings
13.11.1 Laboratory Corporation of America Holdings Company Information
13.11.2 Laboratory Corporation of America Holdings Cancer Minimal Residual Disease Testing Product Portfolios and Specifications
13.11.3 Laboratory Corporation of America Holdings Cancer Minimal Residual Disease Testing Sales, Revenue, Price and Gross Margin (2020-2025)
13.11.4 Laboratory Corporation of America Holdings Main Business Overview
13.11.5 Laboratory Corporation of America Holdings Latest Developments
13.12 Mission Bio
13.12.1 Mission Bio Company Information
13.12.2 Mission Bio Cancer Minimal Residual Disease Testing Product Portfolios and Specifications
13.12.3 Mission Bio Cancer Minimal Residual Disease Testing Sales, Revenue, Price and Gross Margin (2020-2025)
13.12.4 Mission Bio Main Business Overview
13.12.5 Mission Bio Latest Developments
13.13 Natera, Inc.
13.13.1 Natera, Inc. Company Information
13.13.2 Natera, Inc. Cancer Minimal Residual Disease Testing Product Portfolios and Specifications
13.13.3 Natera, Inc. Cancer Minimal Residual Disease Testing Sales, Revenue, Price and Gross Margin (2020-2025)
13.13.4 Natera, Inc. Main Business Overview
13.13.5 Natera, Inc. Latest Developments
13.14 NeoGenomics Laboratories
13.14.1 NeoGenomics Laboratories Company Information
13.14.2 NeoGenomics Laboratories Cancer Minimal Residual Disease Testing Product Portfolios and Specifications
13.14.3 NeoGenomics Laboratories Cancer Minimal Residual Disease Testing Sales, Revenue, Price and Gross Margin (2020-2025)
13.14.4 NeoGenomics Laboratories Main Business Overview
13.14.5 NeoGenomics Laboratories Latest Developments
13.15 Opko Health
13.15.1 Opko Health Company Information
13.15.2 Opko Health Cancer Minimal Residual Disease Testing Product Portfolios and Specifications
13.15.3 Opko Health Cancer Minimal Residual Disease Testing Sales, Revenue, Price and Gross Margin (2020-2025)
13.15.4 Opko Health Main Business Overview
13.15.5 Opko Health Latest Developments
13.16 Quest Diagnostics Incorporated
13.16.1 Quest Diagnostics Incorporated Company Information
13.16.2 Quest Diagnostics Incorporated Cancer Minimal Residual Disease Testing Product Portfolios and Specifications
13.16.3 Quest Diagnostics Incorporated Cancer Minimal Residual Disease Testing Sales, Revenue, Price and Gross Margin (2020-2025)
13.16.4 Quest Diagnostics Incorporated Main Business Overview
13.16.5 Quest Diagnostics Incorporated Latest Developments
13.17 Sysmex Corporation
13.17.1 Sysmex Corporation Company Information
13.17.2 Sysmex Corporation Cancer Minimal Residual Disease Testing Product Portfolios and Specifications
13.17.3 Sysmex Corporation Cancer Minimal Residual Disease Testing Sales, Revenue, Price and Gross Margin (2020-2025)
13.17.4 Sysmex Corporation Main Business Overview
13.17.5 Sysmex Corporation Latest Developments
13.18 Genetron Health
13.18.1 Genetron Health Company Information
13.18.2 Genetron Health Cancer Minimal Residual Disease Testing Product Portfolios and Specifications
13.18.3 Genetron Health Cancer Minimal Residual Disease Testing Sales, Revenue, Price and Gross Margin (2020-2025)
13.18.4 Genetron Health Main Business Overview
13.18.5 Genetron Health Latest Developments
14 Research Findings and Conclusion
听
听
*If Applicable.
